uniQure announced additional positive data from its Phase I/II studies for ifezuntirgene inilparvovec in Huntington's disease, showing meaningful slowing of disease progression at 48 months in high-dose patients. This data, particularly the strong treatment effects at 36 months, is crucial for the ongoing BLA submission and suggests a significant step towards a potential disease-modifying treatment for a condition with no current approved options.
uniQure (QURE) released updated positive data from its Phase I/II studies for ifezuntirgene inilparvovec, a gene therapy for Huntington's disease. The data indicates a meaningful slowing of disease progression, with cUHDRS showing 44% slowing at 48 months (p=0.144) and TFC showing 61% slowing (p=0.008). More importantly, at 36 months, the regulatory anchor for their BLA, the data showed 80% slowing based on cUHDRS (p=0.005) and 67% based on TFC (p=0.011). This is a significant catalyst for uniQure as it strengthens their regulatory submission for a disease with no approved disease-modifying treatments. The short-term implication is likely a positive stock reaction for QURE, while the long-term opportunity lies in potentially bringing the first disease-modifying therapy to market, which would be a major revenue driver. The key risk is that despite the positive nominal p-values, the 48-month cUHDRS data was not statistically significant, and the 'understated' effect due to missing data and survivor bias will need to be carefully evaluated by regulators.